<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cysticercosis: Treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cysticercosis: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cysticercosis: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">A Clinton White, Jr, MD, FACP, FIDSA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cysticercosis is caused by the larval stage (metacestode) of the pork tapeworm <em>Taenia solium</em>. Clinical syndromes related to this parasite include neurocysticercosis (NCC) and extraneural cysticercosis. NCC, in turn, is divided into parenchymal and extraparenchymal forms. Extraparenchymal forms include intraventricular, subarachnoid, spinal, and ocular disease. Treatment must be individualized based on the disease manifestations.</p><p>Guidelines on management of neurocysticercosis were published in 2021 by the World Health Organization; guidelines on diagnosis and treatment were published in 2018 by the Infectious Diseases Society of America and the American Society of Tropical Medicine and Hygiene [<a href="#rid1">1,2</a>].</p><p>The treatment of cysticercosis will be reviewed here. The epidemiology, transmission, prevention, clinical features, and diagnosis of cysticercosis and the life cycle of <em>T. solium</em> are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5693.html" rel="external">"Cysticercosis: Epidemiology, transmission, and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/5678.html" rel="external">"Cysticercosis: Clinical manifestations and diagnosis"</a>.)</p><p>The approach to treatment of tapeworm infection with <em>T. solium</em> is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5685.html" rel="external">"Tapeworm infections"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>Stages of cysticercosis include an initial (viable) phase, a degenerating phase, and a nonviable phase  (<a class="graphic graphic_table graphicRef117224" href="/z/d/graphic/117224.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef117366" href="/z/d/graphic/117366.html" rel="external">figure 1</a> and <a class="graphic graphic_picture graphicRef117260" href="/z/d/graphic/117260.html" rel="external">picture 1</a> and <a class="graphic graphic_diagnosticimage graphicRef117262" href="/z/d/graphic/117262.html" rel="external">image 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Viable cysticerci are round, hypodense lesions (usually 5 to 20 mm in diameter) on computed tomography (CT). Viable cysticerci do not cause much inflammation in surrounding tissues and typically do not enhance after contrast administration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cysticerci degenerate when attacked by the host immune response. The cyst wall increases in density and is often accompanied by surrounding edema and/or contrast enhancement; such findings reflect the host inflammatory response against the parasite and are frequently associated with seizures. In many cases, enhancing cysticerci retain features of viable cysticerci, such as ring enhancing lesions. When the cyst fluid begins to increase in density, the cysts are thought to no longer be viable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonviable cysticerci are solid, calcified nodular lesions (usually 2 to 4 mm in diameter; range 1 to 10 mm); they are usually nonenhancing but may be associated with perilesional edema in some cases. They are also associated with seizures.</p><p></p><p>Cysticerci may be present in more than one anatomic site. In addition, cysticerci at different stages in their natural history may be present simultaneously; for example, at any one time, a patient may have some non-inflamed viable cysts, some enhancing cysts, and/or some calcified cysts.</p><p>In general, treatment should focus on the more severe manifestations of disease and/or the manifestations with greatest likelihood response to therapy. For example, if a patient has intraventricular lesions with hydrocephalus as well as intraparenchymal disease, a number of interventions are needed ( endoscopic removal, anti-inflammatory therapy, antiparasitic therapy, antiseizure medication therapy). The initial focus should be on management of obstructive hydrocephalus, which is a contraindication to antiparasitic therapy.</p><p>Issues related to radiographic findings are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/5678.html" rel="external">"Cysticercosis: Clinical manifestations and diagnosis", section on 'Radiographic imaging'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">INITIAL MANAGEMENT</span><span class="headingEndMark"> — </span>The initial approach to patients with NCC consists of managing acute symptoms if present, such as increased intracranial pressure (via surgical intervention and/or corticosteroids) and seizures (via antiseizure medications). Initiation of antiparasitic therapy is never urgent and should only be a consideration after initial symptomatic therapy. Thereafter, clinical decisions should be tailored to individual patient circumstances, as discussed in the sections below [<a href="#rid3">3-5</a>].</p><p class="headingAnchor" id="H3008540741"><span class="h2">Managing elevated intracranial pressure</span><span class="headingEndMark"> — </span>Signs and symptoms of elevated intracranial pressure (headache, nausea/vomiting, papilledema, and somnolence) associated with parenchymal disease may occur in the setting of diffuse cerebral edema on neuroimaging. Management of diffuse cerebral edema consists of corticosteroid therapy (<a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> 0.2 to 0.4 mg/kg per day) to reduce inflammation. (See <a class="local">'Disseminated disease with or without encephalitis'</a> below.)</p><p>Causes of elevated intracranial pressure associated with extraparenchymal disease include obstructive hydrocephalus (associated with intraventricular disease) and communicating hydrocephalus (associated with subarachnoid disease) [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Management of obstructive hydrocephalus usually consists of a surgical approach (via removal of an obstructing cysticercus or placement of an external ventricular drain or shunt). (See <a class="local">'Obstructive hydrocephalus due to intraventricular cyst'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of communicating hydrocephalus consists of cerebrospinal fluid diversion via ventriculoperitoneal shunt or third ventriculostomy. (See <a class="local">'Communicating hydrocephalus due to subarachnoid disease'</a> below.)</p><p></p><p>Antiparasitic therapy is contraindicated in patients with signs or symptoms of elevated intracranial pressure, regardless of the cause. Such patients should only be considered for antiparasitic therapy if elevated pressure has resolved.</p><p class="headingAnchor" id="H1899469045"><span class="h2">Antiseizure medication therapy</span><span class="headingEndMark"> — </span>Patients with seizures should be managed with antiseizure medication therapy. Even in the case of a single seizure, NCC lesion(s) serve a nidus for recurrent seizures (focal epilepsy) [<a href="#rid1">1,2,6</a>].</p><p>The choice of antiseizure medication should be guided by local availability, cost, drug interactions, and potential side effects [<a href="#rid1">1,2,6</a>]. Most reports on management of seizures in the setting of NCC describe use of <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> or <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>. Newer therapies (such as <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a>) are likely better tolerated, with fewer drug-drug interactions [<a href="#rid7">7</a>]. However, one study suggested that seizure control may be better with carbamazepine than with levetiracetam [<a href="#rid8">8</a>]. In a retrospective review of children with seizures from single enhancing lesions, children treated with <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">lacosamide</a> had fewer side effects and similar seizure control compared to children treated with <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a> [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults"</a>.)</p><p class="headingAnchor" id="H1714389283"><span class="h1">PARENCHYMAL DISEASE</span></p><p class="headingAnchor" id="H1558433820"><span class="h2">Medical management</span><span class="headingEndMark"> — </span>The approach to management of parenchymal neurocysticercosis (NCC) should be guided by findings on radiographic imaging  (<a class="graphic graphic_table graphicRef117225" href="/z/d/graphic/117225.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef117226" href="/z/d/graphic/117226.html" rel="external">table 3</a>). (See <a class="local">'General principles'</a> above.)</p><p class="headingAnchor" id="H2119553858"><span class="h3">Prior to antiparasitic therapy</span><span class="headingEndMark"> — </span>Prior to initiation of antiparasitic therapy for cysticercosis, all patients should have an ophthalmologic examination to exclude ocular cysticercosis [<a href="#rid1">1,2</a>]. Inflammation around degenerating cysticerci in the eye (particularly in the setting of antiparasitic therapy) can threaten vision. (See  <a class="medical medical_review" href="/z/d/html/5678.html" rel="external">"Cysticercosis: Clinical manifestations and diagnosis", section on 'Orbital and ocular lesions'</a>.)</p><p>In addition, patients who are likely to require prolonged corticosteroids should also undergo screening for latent tuberculosis infection as well as screening or empiric therapy for strongyloidiasis. (See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a> and  <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">"Strongyloidiasis"</a>.) </p><p class="headingAnchor" id="H760112642"><span class="h3">Antiparasitic therapy</span><span class="headingEndMark"> — </span>The potential benefits of antiparasitic therapy include hastened resolution of active cysts, diminished seizure risk, and reduced likelihood of recurrent hydrocephalus [<a href="#rid1">1-3</a>]. The major potential risk of antiparasitic therapy is exacerbation of neurologic symptoms due to inflammation around the degenerating cyst, particularly in patients with a large number of lesions or elevated intracranial pressure.</p><p class="headingAnchor" id="H511111273"><span class="h4">Patient selection</span><span class="headingEndMark"> — </span>Antiparasitic therapy is warranted for patients with viable and/or degenerating cysts on neuroimaging. Antiparasitic therapy should not be administered in the following circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>Untreated hydrocephalus (see <a class="local">'Obstructive hydrocephalus due to intraventricular cyst'</a> below and <a class="local">'Communicating hydrocephalus due to subarachnoid disease'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse cerebral edema associated with numerous parasites (eg, cysticercal encephalitis) (See <a class="local">'Disseminated disease with or without encephalitis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of calcified lesion(s) only (See <a class="local">'Patients with calcified nonviable lesion(s)'</a> below.)</p><p></p><p class="headingAnchor" id="H3776653286"><span class="h4">Choice of regimen</span><span class="headingEndMark"> — </span>Antiparasitic regimens for treatment of patients with viable and/or degenerating cysts on neuroimaging include <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> and combination therapy with albendazole plus <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">praziquantel</a>.</p><p>The choice of antiparasitic regimen depends on the burden of disease [<a href="#rid1">1,2,10-13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with one to two cysts, treatment consists of <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> (15 mg/kg per day in two daily doses up to 1200 mg per day, with food).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with more than two cysts, treatment consists of <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> (15 mg/kg per day in two daily doses up to 1200 mg per day, with food) and <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">praziquantel</a> (50 mg/kg per day in three daily doses).</p><p></p><p>Adjunctive corticosteroids should be administered prior to and during antiparasitic therapy [<a href="#rid1">1,2</a>]. (See <a class="local">'Adjunctive use with antiparasitic therapy'</a> below.)</p><p>The above approach to antiparasitic therapy is supported by a randomized trial including 120 patients in Peru with viable parenchymal neurocysticercosis (VPN) and seizures; patients were treated with antiseizure medications and randomized to treatment with <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> (800 mg daily for 10 days) plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (6 mg daily for 10 days) or double placebo [<a href="#rid13">13</a>]. The patients were followed for 30 months or until they were seizure free for six months after tapering of antiseizure therapy. The patients in the treatment arm had fewer generalized seizures (22 versus 68; 67 percent reduction), although there was no significant difference in the overall number of seizures or the number of patients with seizures. The patients in the treatment arm were more likely to have radiographic resolution of intracranial cystic lesions during the 30-month follow-up period, but there was no difference in the development of calcifications between the groups. These findings were confirmed by a subsequent trial performed in Ecuador [<a href="#rid14">14</a>].</p><p>Evidence for the management of patients with a solitary cyst includes a systematic review and meta-analysis of 15 randomized trials; 10 trials included 765 patients treated with antiseizure medication therapy with or without <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a>, and 5 trials included 457 people treated with antiseizure medication therapy with or without corticosteroids [<a href="#rid15">15</a>]. Treatment with albendazole was associated with higher rates of seizure freedom (odds ratio [OR] 2.45, 95% CI 1.49-4.03) and higher rates of radiographic resolution (OR 2.09, 95% CI 1.41-3.00). Treatment with albendazole did not alter the likelihood of residual calcification, . A network analysis suggested that a regimen of corticosteroids plus albendazole was associated with a decreased risk of seizure recurrence (OR 0.32, 95% CI 0.10-0.93) [<a href="#rid10">10</a>].</p><p>The combination of <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> and <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">praziquantel</a> has been associated with a higher rate of radiographic resolution than albendazole alone [<a href="#rid16">16-19</a>]. In one randomized trial including 124 patients with VPN randomized to treatment with standard-dose albendazole (15 mg/kg/day), high-dose albendazole (22.5 mg/kg/day), or combination therapy with both albendazole (15 mg/kg/day) and praziquantel (50 mg/kg/day), complete radiographic resolution was observed after six months in 68 percent of patients with more than two cystic lesions treated with combination therapy (compared with 5 percent treated with standard-dose albendazole and 25 percent treated with high-dose albendazole) [<a href="#rid18">18</a>]. Similar findings were observed in another trial [<a href="#rid19">19</a>]. In a randomized trial of children with persistent lesions despite prior antiparasitic drugs, those who were retreated with albendazole plus praziquantel had a greater proportion with resolution and larger decrease in cyst volume than those treated with albendazole [<a href="#rid20">20</a>]. </p><p class="headingAnchor" id="H1170601420"><span class="h4">Duration of therapy</span><span class="headingEndMark"> — </span>The duration of antiparasitic therapy for treatment of parenchymal neurocysticercosis is 7 to 14 days in most cases.</p><p class="headingAnchor" id="H1312982321"><span class="h3">Corticosteroids</span></p><p class="headingAnchor" id="H4199100988"><span class="h4">Adjunctive use with antiparasitic therapy</span><span class="headingEndMark"> — </span>Corticosteroids should always be administered concomitantly with antiparasitic therapy [<a href="#rid1">1,2</a>]. Use of corticosteroids during antiparasitic therapy is associated with fewer seizures [<a href="#rid1">1,2,10,21</a>]. Administration of antiparasitic therapy may hasten degeneration of viable cysts, thereby increasing inflammation and increasing risk for seizure. In some cases, inflammation associated with antiparasitic therapy can be so severe that it leads to disability or death.</p><p>For patients with single enhancing lesions, use of adjunctive corticosteroids has been associated with reduction in the likelihood of seizure recurrence [<a href="#rid22">22</a>]. This was illustrated in a network meta-analysis including 14 randomized trials; among patients treated with combination <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> and corticosteroids, corticosteroids alone, albendazole alone, or conservative management, combination therapy was the only regimen that significantly reduced the risk of seizure recurrence relative to conservative treatment (OR 0.32, 95% CI 0.10-0.93) [<a href="#rid10">10</a>]. Limitations of this network meta-analysis include high risk of bias and short follow-up duration in most studies.</p><p>For patients with multiple viable cysts, administration of antiparasitic therapy without corticosteroids has been associated with increased seizures shortly after initiation of treatment. In open-label studies, use of adjunctive corticosteroids has been shown to abrogate this response [<a href="#rid21">21</a>]. In addition, a trend toward fewer seizures with enhanced steroid dosing was suggested in a randomized trial [<a href="#rid23">23</a>]; however, that trial was underpowered.</p><p class="headingAnchor" id="H2946876226"><span class="h5">Dose and duration</span><span class="headingEndMark"> — </span>The optimal adjunctive corticosteroid regimen is uncertain; commonly used regimens include <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (1 mg/kg per day) or <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (0.1 mg/kg per day) begun at least one day prior to antiparasitic therapy, continued for the duration of antiparasitic therapy, and followed by a rapid taper over a few days.</p><p>More intensive steroid dosing (such as <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> 8 mg/day for 28 days followed by a taper) may be associated with fewer seizures; further study is needed [<a href="#rid23">23</a>]. In parenchymal neurocysticercosis, dexamethasone doses &gt;6.5 mg/day have been associated with less frequent development of calcifications [<a href="#rid24">24</a>]. </p><p class="headingAnchor" id="H1681390659"><span class="h4">Symptomatic use</span><span class="headingEndMark"> — </span>Use of corticosteroids is warranted for management of cysticercal encephalitis (diffuse cerebral edema associated with multiple inflamed cysticerci). (See <a class="local">'Disseminated disease with or without encephalitis'</a> below.)</p><p>Routine use of corticosteroids is not warranted for patients with calcified lesions and perilesional edema. In such cases when corticosteroids are tapered or stopped, rebound edema may occur [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H4242426142"><span class="h2">Disseminated disease with or without encephalitis</span><span class="headingEndMark"> — </span>Patients with disseminated disease may be categorized as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Disseminated parenchymal neurocysticercosis refers to patients with more than 20 lesions within the brain parenchyma. These include cases with cysticercal encephalitis and heavy non-encephalitic cysticercosis [<a href="#rid25">25</a>]. There is limited information on optimal treatment in these cases; some patients have been treated with corticosteroid and antiparasitic therapy [<a href="#rid26">26,27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cysticercal encephalitis refers to disseminated parenchymal neurocysticercosis with diffuse cerebral edema associated from multiple inflamed cysticerci). Cysticercal encephalitis is a contraindication for antiparasitic therapy, since enhanced parasite killing can exacerbate the host inflammatory response, leading to diffuse cerebral edema and potential transtentorial herniation [<a href="#rid25">25</a>]. Most cases of cysticercal encephalitis improve with high-dose corticosteroid therapy (eg, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> 0.2 to 0.4 mg/kg per day). The duration of therapy should be individualized based on the clinical and radiographic resolution of edema. In most cases, the cysticerci resolve without antiparasitic therapy.</p><p></p><p class="headingAnchor" id="H1792784184"><span class="h2">Patients with calcified nonviable lesion(s)</span><span class="headingEndMark"> — </span>Management of patients with calcified parenchymal neurocysticercosis (CPN; in the absence of viable or enhancing lesions) consists of symptomatic therapy.</p><p>Calcified lesions do not contain viable parasites so there is no role for antiparasitic or anti-inflammatory therapy [<a href="#rid2">2</a>]. Routine use of corticosteroids is not warranted for patients with calcified lesions associated with perilesional edema. In such cases when corticosteroids are tapered or stopped, rebound edema can occur.</p><p>Patients with seizures warrant antiseizure medication therapy; in such patients, calcified lesions increase the risk of recurrent seizures and chronic epilepsy [<a href="#rid6">6,28</a>]. No antiseizure medication therapy is warranted for asymptomatic patients.</p><p>For patients with a single seizure and no recurrence within six months, tapering and discontinuation of antiseizure medication therapy is reasonable [<a href="#rid6">6,28</a>]. A minority of cases of neurocysticercosis go on to develop refractory seizures, especially temporal lobe seizures. These are frequently associated with hippocampal atrophy. Cures have been noted with resection of the anterior temporal lobe [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H156589016"><span class="h1">EXTRAPARENCHYMAL DISEASE</span></p><p class="headingAnchor" id="H2009796710"><span class="h2">Elevated intracranial pressure</span><span class="headingEndMark"> — </span>Management of elevated intracranial pressure is discussed above. (See <a class="local">'Managing elevated intracranial pressure'</a> above.)</p><p class="headingAnchor" id="H2324774925"><span class="h2">Obstructive hydrocephalus due to intraventricular cyst</span><span class="headingEndMark"> — </span>Patients with intraventricular neurocysticercosis (IVN) and hydrocephalus associated with altered mental status or impending herniation may require emergent cerebrospinal fluid (CSF) diversion via ventriculostomy, placement of a ventriculoperitoneal shunt, or neuroendoscopic cyst removal and third ventriculostomy [<a href="#rid2">2,30-32</a>]. Definitive therapy for patients with cyst(s) causing obstruction consists of cyst removal if possible. </p><p>Management of patients with mild or intermittent symptoms of hydrocephalus depends on whether the cysticerci are adherent. In general, cysticerci that appear intact and are not inflamed may be regarded as nonadherent:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with nonadherent IVN in the lateral or third ventricle, cysticerci should be removed endoscopically if feasible [<a href="#rid2">2,30,31</a>]. For patients with nonadherent IVN in the fourth ventricle, cysticerci should be removed endoscopically, via an open approach, or stereotactic removal; the approach depends on the experience of the surgeon and whether there is dilation of the aqueduct of Sylvius [<a href="#rid2">2,31,33,34</a>]. In many cases, the fourth ventricle is more easily accessed via a suboccipital approach. Most cases of isolated nonadherent IVN can be cured by removal and do not require antiparasitic therapy if all cysticerci are removed [<a href="#rid32">32,35</a>]. There is no role for preoperative antiparasitic therapy, which can lead to an inflammatory response and reduce the likelihood of successful cyst removal. For cases in which not all cysticerci are removed, subsequent antiparasitic therapy (<a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> 15 mg/kg per day in two daily doses up 1200 mg per day, with food for 10 to 14 days) and anti-inflammatory therapy with corticosteroids is warranted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with adherent IVN, management consists of CSF diversion via ventriculoperitoneal shunt (rather than cyst removal, which is associated with increased risk of complications), followed by antiparasitic therapy (<a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> 15 mg/kg per day in two daily doses up 1200 mg per day, with food for 10 to 14 days) and anti-inflammatory therapy [<a href="#rid36">36</a>] (see <a class="local">'Antiparasitic therapy'</a> above and <a class="local">'Corticosteroids'</a> above). Shunt placement prior to antiparasitic therapy is important since precipitation of hydrocephalus with antiparasitic therapy has been described.</p><p></p><p>Corticosteroids are often administered prior to, during, and following neurosurgical procedures to reduce inflammation and brain edema. There are no high-quality data on the efficacy of this approach for surgical management of IVN, but it is well established for other neurologic diseases.</p><p class="headingAnchor" id="H956456277"><span class="h2">Communicating hydrocephalus due to subarachnoid disease</span><span class="headingEndMark"> — </span>Subarachnoid (racemose) NCC can present with communicating hydrocephalus, meningitis, stroke, or focal neurologic findings [<a href="#rid2">2,37,38</a>]. Subarachnoid NCC is associated with a high case fatality rate [<a href="#rid39">39</a>]. Mixed forms also occur. (See  <a class="medical medical_review" href="/z/d/html/5678.html" rel="external">"Cysticercosis: Clinical manifestations and diagnosis", section on 'Subarachnoid lesions'</a>.)</p><p>In the setting of subarachnoid neurocysticercosis and communicating hydrocephalus, management consists of CSF diversion via ventriculoperitoneal shunt, followed by antiparasitic and anti-inflammatory (corticosteroid) therapy [<a href="#rid2">2,37,38,40</a>].</p><p>In the setting of subarachnoid neurocysticercosis and no hydrocephalus, management consists of antiparasitic therapy and anti-inflammatory (corticosteroid) therapy. Endoscopic removal/debulking of subarachnoid cysts via third ventriculostomy or other approaches have been described; however, the role for this intervention is controversial given the risk of bleeding and neurologic complications [<a href="#rid2">2,41-43</a>].</p><p>Subarachnoid cysts do not respond to typical durations and doses of antiparasitic therapy used for parenchymal neurocysticercosis [<a href="#rid44">44</a>]. Therapeutic options include prolonged administration of <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> (15 mg/kg per day), cycles of higher doses of albendazole (30 mg/kg/day) or combination therapy with albendazole (15 mg/kg per day) plus <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">praziquantel</a> (50 mg/kg per day) [<a href="#rid2">2,37,40,45,46</a>]. However, higher doses of albendazole (22.5 mg/kg per day) have been associated with an increased frequency of calcifications, a risk factor for recurrent seizures [<a href="#rid24">24</a>]. For prolonged albendazole therapy, antiparasitic therapy should be continued until there is radiographic resolution of cysticerci; a year or more of treatment may be required. In some cases, the radiologic changes may persist, but negative studies of CSF for parasite antigen and/or quantitative polymerase chain reaction allow discontinuation of therapy [<a href="#rid47">47</a>]. Patients treated with albendazole for &gt;14 days warrant monitoring for hepatotoxicity and leukopenia [<a href="#rid2">2</a>]. Blood counts and liver and liver enzymes should be checked weekly during the initial month of therapy and monthly thereafter. Follow-up neuroimaging should be performed at least every six months to monitor response to therapy.</p><p>Concomitant administration of anti-inflammatory treatment such as corticosteroids is essential, as antiparasitic therapy exacerbates inflammation. A reasonable approach is to use <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (up to 60 mg per day) or <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (up to 12 to 24 mg per day), beginning a few days before initiation of antiparasitic therapy. For patients requiring a prolonged course of therapy (more than a couple weeks), <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> may be used as a steroid-sparing agent [<a href="#rid2">2,48,49</a>]. Methotrexate doses usually start at 7.5 mg weekly and can be increased, using protocols similar to those used for rheumatoid arthritis (see  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis"</a>). Tumor necrosis factor inhibitors have also been used as steroids sparing agents, usually in addition to methotrexate.</p><p>There are no controlled clinical trials of treatment for subarachnoid neurocysticercosis [<a href="#rid37">37,38,46</a>]. In one case series including 30 patients, treatment with prolonged courses of <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> (median 0.55 year) and/or <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">praziquantel</a> (median 0.96 year) led to sustained inactive disease in 96 percent of cases [<a href="#rid37">37</a>]. In another series including 31 patients treated with high-dose albendazole (30 mg/kg/day for 10 days) with <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (0.4 mg/kg/day for 13 days) followed by a <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> taper a complete response to a single course of therapy was observed in 26 percent of cases [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H755550469"><span class="h2">Giant subarachnoid cyst</span><span class="headingEndMark"> — </span>In the setting of giant subarachnoid cysticerci (&gt;5 cm in diameter, frequently accompanied by cerebral edema and mass effect), management consists of corticosteroids; rarely, surgical decompression is required. Once mass effect is controlled, management is as described above [<a href="#rid40">40</a>]. </p><p>The above approach to antiparasitic therapy is supported by a series including 33 patients with subarachnoid cysts at least 5 cm in diameter and intracranial hypertension [<a href="#rid40">40</a>]. All patients received <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> for four weeks; 10 patients subsequently received treatment with <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">praziquantel</a> for four weeks. In addition, 17 patients received a second course of albendazole, 3 received a third course, and 1 received a fourth course. After a median of 59 months of follow-up, all 33 patients had improved and the cysts had disappeared or become calcified. Of the 22 patients with a history of seizures, 11 continued to receive antiseizure medications. (See <a class="local">'Communicating hydrocephalus due to subarachnoid disease'</a> above.)</p><p class="headingAnchor" id="H3335863304"><span class="h2">Spinal lesions</span><span class="headingEndMark"> — </span>Management of spinal neurocysticercosis should be individualized based on symptoms, anatomic location of cysticerci, degree of arachnoiditis, and surgical expertise [<a href="#rid2">2</a>]. There are anecdotes of good responses to medical and/or surgical therapy, but there are no good data supporting one approach over the other [<a href="#rid50">50,51</a>].</p><p>In the setting of spinal neurocysticercosis with spinal cord compression and myelopathy (paraparesis or incontinence), treatment with high-dose corticosteroids should be considered, either alone or in conjunction with antiparasitic therapy.</p><p class="headingAnchor" id="H1207840755"><span class="h2">Ocular lesions</span><span class="headingEndMark"> — </span>Management of intraocular cysticercosis consists of surgical removal [<a href="#rid2">2,52,53</a>]. In one series including 45 patients with intraocular cysticercosis, surgical removal was feasible in all cases; reattachment of the retina was accomplished in 87 percent of 22 eyes, and 67 percent recovered ambulatory vision [<a href="#rid52">52</a>].</p><p>Management of cysticercal involvement of the extraocular muscles consists of <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> (15 mg/kg per day in two daily doses up 1200 mg per day, with food for 10 to 14 days) and corticosteroids (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg per day or <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> 0.1 mg/kg per day) [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H2706125769"><span class="h2">Cysticercosis outside the central nervous system</span><span class="headingEndMark"> — </span>In general, management of patients with symptomatic subcutaneous or intramuscular cysticerci consists of nonsteroidal anti-inflammatory medication. Excision is reasonable for symptomatic solitary lesions. Asymptomatic patients do not require specific therapy.</p><p>Patients with extraneural cysticercosis should undergo radiographic imaging of the brain to evaluate for neurocysticercosis. (See  <a class="medical medical_review" href="/z/d/html/5678.html" rel="external">"Cysticercosis: Clinical manifestations and diagnosis", section on 'Radiographic imaging'</a>.)</p><p class="headingAnchor" id="H3895902807"><span class="h1">FOLLOW-UP AND MONITORING</span></p><p class="headingAnchor" id="H2946178573"><span class="h2">Repeat neuroimaging</span><span class="headingEndMark"> — </span>Follow-up imaging should be performed every six months following completion of initial antiparasitic therapy, until there is resolution of the cystic lesion [<a href="#rid2">2</a>]. Patients with persistent viable or enhancing lesions on follow-up imaging warrant a repeat course of antiparasitic therapy [<a href="#rid13">13,14,20</a>].</p><p class="headingAnchor" id="H2302333571"><span class="h2">Duration of antiseizure medication therapy</span><span class="headingEndMark"> — </span>The optimal duration of antiseizure medication therapy is uncertain; many patients continue to have seizures following antiparasitic treatment [<a href="#rid13">13,14,54,55</a>]. Risk factors for recurrent seizures include residual cystic lesion or calcification on radiographic imaging, breakthrough seizures, and &gt;2 seizures during the course of the disease [<a href="#rid1">1,2,28,56,57</a>]. Other risk factors include perilesional edema around calcified lesions. </p><p>In patients with multiple lesions, antiseizure medication therapy should be continued for at least 24 months. Tapering and discontinuation of antiseizure medication therapy is reasonable for patients with few seizures prior to antiparasitic therapy, resolution of the cystic lesion(s) on radiographic imaging studies, and no seizures for 24 consecutive months [<a href="#rid1">1,2,58</a>]. In one study, none of 21 patients with complete radiologic resolution had subsequent seizures with 24 months of follow-up [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults"</a>.)</p><p>For patients with a single enhancing lesion, antiseizure medication therapy should be continued for six months or until radiographic resolution of active infection, if longer; after this period, a trial off antiseizure medication therapy is reasonable in patients with no risk factors for recurrent seizures [<a href="#rid1">1,2,22</a>].</p><p>Recurrent seizures should prompt reinitiation of chronic antiseizure medication therapy.</p><p class="headingAnchor" id="H1214320590"><span class="h1">ASYMPTOMATIC INFECTION</span><span class="headingEndMark"> — </span>The optimal approach to management of asymptomatic patients with incidental radiographic findings of cysticercosis is uncertain.</p><p>In general, management of asymptomatic patients with enhancing lesions or viable disease (extremely rare) should be individualized based on patient preference. In studies of the natural history of neurocysticercosis, most cystic lesions resolve with development of calcifications, in the absence of symptoms [<a href="#rid59">59</a>]. However, some patients may prefer antiparasitic therapy; in such cases, the approach is as discussed above. (See <a class="local">'Initial management'</a> above.)</p><p>Asymptomatic patients with nonviable disease do not appear to benefit from any further therapy [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H3367318682"><span class="h1">CHILDREN AND PREGNANT WOMEN</span><span class="headingEndMark"> — </span>Children with neurocysticercosis may be managed as described in the preceding sections; medication dosing should be weight based.</p><p>Pregnant women with elevated intracranial pressure should be managed as described in the preceding sections. Corticosteroids may be used in pregnancy if necessary. The choice of antiseizure medication therapy should take into account potential teratogenicity and pharmacokinetics in pregnancy. Antiparasitic therapy is rarely required emergently and can be deferred until after pregnancy. (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period"</a>.)</p><p class="headingAnchor" id="H884836935"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/127187.html" rel="external">"Society guideline links: Cysticercosis"</a>.)</p><p class="headingAnchor" id="H3252061491"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles -</strong> Cysticercosis is caused by the larval stage of the pork tapeworm <em>Taenia solium</em>. Clinical syndromes related to this parasite include neurocysticercosis (NCC) and extraneural cysticercosis. NCC, in turn, is divided into parenchymal and extraparenchymal forms. Stages of cysticercosis include an initial (viable) phase, a degenerating (enhancing) phase, and a nonviable (calcified) phase  (<a class="graphic graphic_table graphicRef117224" href="/z/d/graphic/117224.html" rel="external">table 1</a>). Cysticerci may be present in more than one anatomic site, and cysticerci at different stages in their natural history may be present simultaneously. (See <a class="local">'General principles'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management</strong> - The initial approach to patients with NCC consists of managing acute symptoms, if present, such as increased intracranial pressure (via surgical intervention and/or corticosteroids) and seizures (via antiseizure medication therapy). Thereafter, a determination should be made regarding the approach to management of antiparasitic and anti-inflammatory therapy; clinical decisions should be tailored to individual patient circumstances. (See <a class="local">'Initial management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prior to antiparasitic therapy</strong> - Prior to initiation of antiparasitic therapy for cysticercosis, all patients should have an ophthalmologic examination to exclude ocular cysticercosis. In addition, patients who are likely to require prolonged corticosteroids should also undergo screening for latent tuberculosis infection as well as screening or empiric therapy for strongyloidiasis. (See <a class="local">'Prior to antiparasitic therapy'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiparasitic therapy </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patient selection</strong> - Antiparasitic therapy is warranted for patients with viable and/or degenerating cysts in the brain parenchyma on neuroimaging. Antiparasitic therapy should not be administered to patients with untreated hydrocephalus, cysticercal encephalitis, or calcified lesions only. (See <a class="local">'Patient selection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of regimen</strong> - Administration of antiparasitic therapy depends on the number and characteristics of the cyst(s) on neuroimaging:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Antiparasitic therapy is not indicated for patients with untreated hydrocephalus, cysticercal encephalitis, or calcified lesions only.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with one to two parenchymal cysts that are viable and/or degenerating, we suggest treatment with <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> rather than no antiparasitic therapy (<a class="grade" href="https:///uptodate/show/grade_4" rel="external">Grade 2A</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with more than two parenchymal cysts that are viable and/or degenerating, we suggest treatment with <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> and <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">praziquantel</a> rather than monotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration</strong> - The duration of antiparasitic therapy is 10 to 14 days in most cases; patients with subarachnoid disease warrant an extended duration of antiparasitic therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Corticosteroid therapy</strong> - We recommend adjunctive administration of corticosteroids with antiparasitic therapy (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). The optimal regimen is uncertain; commonly used regimens include <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (1 mg/kg per day) or <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (0.1 mg/kg per day) begun at least one day prior to antiparasitic therapy, continued for the duration of antiparasitic therapy, and followed by a rapid taper. (See <a class="local">'Adjunctive use with antiparasitic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up and monitoring</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Follow-up neuroimaging should be performed every six months following completion of antiparasitic therapy until radiographic resolution. For patients with persistent lesions on follow-up imaging, we suggest a repeat course of antiparasitic therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Repeat neuroimaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The optimal duration of antiseizure medication therapy is uncertain; many patients continue to have seizures following antiparasitic treatment. For patients with viable and/or multiple lesions, antiseizure medication therapy should be continued for at least 24 months. For patients with a single enhancing lesion, antiseizure medication therapy should be continued for six months or until radiographic resolution of active infection, if longer. (See <a class="local">'Duration of antiseizure medication therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extraparenchymal disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ventricular cysticercosis</strong> - Management of ventricular cysticercosis consists of surgical removal if feasible. Frequently, cysts in the third and lateral ventricles may be removed via a minimally invasive approach; cysts in the fourth ventricle may be removed via minimally invasive surgery or open microdissection. (See <a class="local">'Obstructive hydrocephalus due to intraventricular cyst'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subarachnoid cysticercosis</strong> - Management of subarachnoid cysticercosis consists of more intensive antiparasitic and anti-inflammatory regimens than those used for parenchymal disease. Antiparasitic therapy should be continued until there is radiographic resolution of the cystic lesions, which often requires months of therapy. Anti-inflammatory therapy should be continued for the duration of antiparasitic therapy. (See <a class="local">'Communicating hydrocephalus due to subarachnoid disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Spinal cysticercosis</strong> - Management of spinal neurocysticercosis should be individualized based on symptoms, anatomic location of cysticerci, degree of arachnoiditis, and surgical expertise. Management of intraocular cysticercosis consists of surgical removal. Management of patients with symptomatic subcutaneous or intramuscular cysticerci consists of nonsteroidal anti-inflammatory medication. Excision is reasonable for symptomatic solitary lesions. (See <a class="local">'Spinal lesions'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization. WHO guidelines on management of Taenia solium neurocysticercosis. https://www.who.int/publications/i/item/9789240032231 (Accessed on November 03, 2021).</li><li><a class="nounderline abstract_t">White AC Jr, Coyle CM, Rajshekhar V, et al. Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2018; 66:e49.</a></li><li><a class="nounderline abstract_t">Garcia HH, Gonzalez AE, Gilman RH. Taenia solium Cysticercosis and Its Impact in Neurological Disease. Clin Microbiol Rev 2020; 33.</a></li><li><a class="nounderline abstract_t">Pineda-Reyes R, White AC Jr. Neurocysticercosis: an update on diagnosis, treatment, and prevention. Curr Opin Infect Dis 2022; 35:246.</a></li><li><a class="nounderline abstract_t">Coyle CM. Neurocysticerosis: An Individualized Approach. Infect Dis Clin North Am 2019; 33:153.</a></li><li><a class="nounderline abstract_t">Espino PH, Couper RG, Burneo JG. An update on Neurocysticercosis-related epilepsy. Clin Neurol Neurosurg 2022; 213:107139.</a></li><li><a class="nounderline abstract_t">Kaushal S, Rani A, Chopra SC, Singh G. Safety and efficacy of clobazam versus phenytoin-sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. Neurol India 2006; 54:157.</a></li><li><a class="nounderline abstract_t">Santhosh AP, Kumar Goyal M, Modi M, et al. Carbamazepine versus levetiracetam in epilepsy due to neurocysticercosis. Acta Neurol Scand 2021; 143:242.</a></li><li><a class="nounderline abstract_t">Sharawat IK, Panda PK, Kumar V, Sherwani P. Comparative Efficacy and Safety of Lacosamide and Oxcarbazepine for Seizure Control in Children with Newly Diagnosed Solitary Neurocysticercosis. J Trop Pediatr 2022; 68.</a></li><li><a class="nounderline abstract_t">Zhao BC, Jiang HY, Ma WY, et al. Albendazole and Corticosteroids for the Treatment of Solitary Cysticercus Granuloma: A Network Meta-analysis. PLoS Negl Trop Dis 2016; 10:e0004418.</a></li><li><a class="nounderline abstract_t">Singh G, Murthy JM. Solitary cysticercus granuloma-treatment with albendazole: what is the optimal duration? Neurol India 2010; 58:507.</a></li><li><a class="nounderline abstract_t">Garg D, Sharma S. Albendazole for Neurocysticercosis in Children: How Long is Long Enough? Indian Pediatr 2022; 59:909.</a></li><li><a class="nounderline abstract_t">Garcia HH, Pretell EJ, Gilman RH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004; 350:249.</a></li><li><a class="nounderline abstract_t">Carpio A, Kelvin EA, Bagiella E, et al. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008; 79:1050.</a></li><li><a class="nounderline abstract_t">Otte WM, Singla M, Sander JW, Singh G. Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis. Neurology 2013; 80:152.</a></li><li><a class="nounderline abstract_t">Garcia HH, Lescano AG, Lanchote VL, et al. Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis. Br J Clin Pharmacol 2011; 72:77.</a></li><li><a class="nounderline abstract_t">Kaur S, Singhi P, Singhi S, Khandelwal N. Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J 2009; 28:403.</a></li><li><a class="nounderline abstract_t">Garcia HH, Gonzales I, Lescano AG, et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis 2014; 14:687.</a></li><li><a class="nounderline abstract_t">Garcia HH, Lescano AG, Gonzales I, et al. Cysticidal Efficacy of Combined Treatment With Praziquantel and Albendazole for Parenchymal Brain Cysticercosis. Clin Infect Dis 2016; 62:1375.</a></li><li><a class="nounderline abstract_t">Singh K, Saini AG, Khandelwal N, Singhi P. Efficacy of Combination Therapy of Albendazole and Praziquantel vs Albendazole Monotherapy in Children With Persistent Neurocysticercosis: A Randomized Controlled Trial. J Child Neurol 2022; 37:366.</a></li><li><a class="nounderline abstract_t">deGhetaldi LD, Norman RM, Douville AW Jr. Cerebral cysticercosis treated biphasically with dexamethasone and praziquantel. Ann Intern Med 1983; 99:179.</a></li><li><a class="nounderline abstract_t">Abraham A, Bustos JA, Carabin H, et al. The effectiveness of anti-inflammatory and anti-seizure medication for individuals with single enhancing lesion neurocysticercosis: A meta-analysis and expert group-based consensus recommendations. PLoS Negl Trop Dis 2021; 15:e0009193.</a></li><li><a class="nounderline abstract_t">Garcia HH, Gonzales I, Lescano AG, et al. Enhanced steroid dosing reduces seizures during antiparasitic treatment for cysticercosis and early after. Epilepsia 2014; 55:1452.</a></li><li><a class="nounderline abstract_t">Bustos JA, Arroyo G, Gilman RH, et al. Frequency and Determinant Factors for Calcification in Neurocysticercosis. Clin Infect Dis 2021; 73:e2592.</a></li><li><a class="nounderline abstract_t">Del Brutto OH, Garcia HH. The many facets of disseminated parenchymal brain cysticercosis: A differential diagnosis with important therapeutic implications. PLoS Negl Trop Dis 2021; 15:e0009883.</a></li><li><a class="nounderline abstract_t">Pandey S, Malhotra HS, Garg RK, et al. Quantitative assessment of lesion load and efficacy of 3 cycles of albendazole in disseminated cysticercosis: a prospective evaluation. BMC Infect Dis 2020; 20:220.</a></li><li><a class="nounderline abstract_t">Ganaraja HV, Mahadevan A, Saini J, et al. Disseminated Cysticercosis in Indian Scenario - Experience from a Teaching University Hospital. Neurol India 2022; 70:1032.</a></li><li><a class="nounderline abstract_t">Nash TE, Pretell EJ, Lescano AG, et al. Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol 2008; 7:1099.</a></li><li><a class="nounderline abstract_t">Bianchin MM, Velasco TR, Wichert-Ana L, et al. Understanding the association of neurocysticercosis and mesial temporal lobe epilepsy and its impact on the surgical treatment of patients with drug-resistant epilepsy. Epilepsy Behav 2017; 76:168.</a></li><li><a class="nounderline abstract_t">Rangel-Castilla L, Serpa JA, Gopinath SP, et al. Contemporary neurosurgical approaches to neurocysticercosis. Am J Trop Med Hyg 2009; 80:373.</a></li><li><a class="nounderline abstract_t">Konar S, Kandregula S, Sashidhar A, et al. Endoscopic intervention for intraventricular neurocysticercal cyst: Challenges and outcome analysis from a single institute experience. Clin Neurol Neurosurg 2020; 198:106179.</a></li><li><a class="nounderline abstract_t">Nash TE, Ware JM, Mahanty S. Intraventricular Neurocysticercosis: Experience and Long-Term Outcome from a Tertiary Referral Center in the United States. Am J Trop Med Hyg 2018; 98:1755.</a></li><li><a class="nounderline abstract_t">Torres-Corzo J, Rodriguez-della Vecchia R, Rangel-Castilla L. Bruns syndrome caused by intraventricular neurocysticercosis treated using flexible endoscopy. J Neurosurg 2006; 104:746.</a></li><li><a class="nounderline abstract_t">Saavedra LJ, Vásquez CM, García HH, et al. Stereotactic surgery for neurocysticercosis of the 4th ventricle: illustrative cases. J Neurosurg Case Lessons 2021; 2:CASE21279.</a></li><li><a class="nounderline abstract_t">Milenković Z, Momčilović S, Ignjatovic A, Tasić-Otašević S. Is Antihelminthics Necessary in Postoperative Treatment of Intraventricular Neurocysticercosis? A Systematic Review. World Neurosurg 2023.</a></li><li><a class="nounderline abstract_t">Kelley R, Duong DH, Locke GE. Characteristics of ventricular shunt malfunctions among patients with neurocysticercosis. Neurosurgery 2002; 50:757.</a></li><li><a class="nounderline abstract_t">Nash TE, O'Connell EM, Hammoud DA, et al. Natural History of Treated Subarachnoid Neurocysticercosis. Am J Trop Med Hyg 2020; 102:78.</a></li><li><a class="nounderline abstract_t">Marcin Sierra M, Arroyo M, Cadena Torres M, et al. Extraparenchymal neurocysticercosis: Demographic, clinicoradiological, and inflammatory features. PLoS Negl Trop Dis 2017; 11:e0005646.</a></li><li><a class="nounderline abstract_t">Abanto J, Blanco D, Saavedra H, et al. Mortality in Parenchymal and Subarachnoid Neurocysticercosis. Am J Trop Med Hyg 2021; 105:176.</a></li><li><a class="nounderline abstract_t">Proaño JV, Madrazo I, Avelar F, et al. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 2001; 345:879.</a></li><li><a class="nounderline abstract_t">Proaño JV, Torres-Corzo J, Rodríguez-Della Vecchia R, et al. Intraventricular and subarachnoid basal cisterns neurocysticercosis: a comparative study between traditional treatment versus neuroendoscopic surgery. Childs Nerv Syst 2009; 25:1467.</a></li><li><a class="nounderline abstract_t">Burgos-Sosa E, Bergna-Vazquez P, Mendizabal-Guerra R, Ayala-Arcipreste A. Microsurgical and endoscopic-assisted supraorbital keyhole approach for intra-suprasellar cysticercosis. Surg Neurol Int 2023; 14:328.</a></li><li><a class="nounderline abstract_t">Wahlster S, Zunt J, Bonow R. Surgical Debulking Before Medical Management in a Patient With Massive Racemose Neurocysticercosis. Neurology 2023; 101:627.</a></li><li><a class="nounderline abstract_t">White AC, Fleury A. Optimal Treatment for Subarachnoid Neurocysticercosis: Closer, but Not There yet. Am J Trop Med Hyg 2020; 102:1.</a></li><li><a class="nounderline abstract_t">Göngora-Rivera F, Soto-Hernández JL, González Esquivel D, et al. Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology 2006; 66:436.</a></li><li><a class="nounderline abstract_t">Osorio R, Carrillo-Mezo R, Romo ML, et al. Factors Associated With Cysticidal Treatment Response in Extraparenchymal Neurocysticercosis. J Clin Pharmacol 2019; 59:548.</a></li><li><a class="nounderline abstract_t">O'Connell EM, Harrison S, Dahlstrom E, et al. A Novel, Highly Sensitive Quantitative Polymerase Chain Reaction Assay for the Diagnosis of Subarachnoid and Ventricular Neurocysticercosis and for Assessing Responses to Treatment. Clin Infect Dis 2020; 70:1875.</a></li><li><a class="nounderline abstract_t">Mitre E, Talaat KR, Sperling MR, Nash TE. Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis. Clin Infect Dis 2007; 44:549.</a></li><li><a class="nounderline abstract_t">Anand P, Mukerji SS, Thon J, et al. Steroid-sparing agents for the treatment of inflammation in complicated neurocysticercosis. Neurol Neuroimmunol Neuroinflamm 2019; 6.</a></li><li><a class="nounderline abstract_t">Barrie U, Badejo O, Aoun SG, et al. Systematic Review and Meta-Analysis of Management Strategies and Outcomes in Adult Spinal Neurocysticercosis. World Neurosurg 2020; 138:504.</a></li><li><a class="nounderline abstract_t">Torres-Corzo JG, Islas-Aguilar MA, Cervantes DS, Chalita-Williams JC. The Role of Flexible Neuroendoscopy in Spinal Neurocysticercosis: Technical Note and Report of 3 Cases. World Neurosurg 2019; 130:77.</a></li><li><a class="nounderline abstract_t">Sharma T, Sinha S, Shah N, et al. Intraocular cysticercosis: clinical characteristics and visual outcome after vitreoretinal surgery. Ophthalmology 2003; 110:996.</a></li><li><a class="nounderline abstract_t">Pujari A, Bhaskaran K, Modaboyina S, et al. Cysticercosis in ophthalmology. Surv Ophthalmol 2022; 67:544.</a></li><li><a class="nounderline abstract_t">Walton D, Castell H, Collie C, et al. Antiepileptic drugs for seizure control in people with neurocysticercosis. Cochrane Database Syst Rev 2021; 11:CD009027.</a></li><li><a class="nounderline abstract_t">Frackowiak M, Sharma M, Singh T, et al. Antiepileptic drugs for seizure control in people with neurocysticercosis. Cochrane Database Syst Rev 2019; 10:CD009027.</a></li><li><a class="nounderline abstract_t">Rajshekhar V, Jeyaseelan L. Seizure outcome in patients with a solitary cerebral cysticercus granuloma. Neurology 2004; 62:2236.</a></li><li><a class="nounderline abstract_t">Carpio A, Chang M, Zhang H, et al. Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis. Epilepsia 2019; 60:1820.</a></li><li><a class="nounderline abstract_t">Del Brutto OH. Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis. Neurology 1994; 44:1706.</a></li><li><a class="nounderline abstract_t">Fleury A, Gomez T, Alvarez I, et al. High prevalence of calcified silent neurocysticercosis in a rural village of Mexico. Neuroepidemiology 2003; 22:139.</a></li></ol></div><div id="topicVersionRevision">Topic 5681 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/publications/i/item/9789240032231" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization. WHO guidelines on management of Taenia solium neurocysticercosis. https://www.who.int/publications/i/item/9789240032231 (Accessed on November 03, 2021).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29481580" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32461308" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Taenia solium Cysticercosis and Its Impact in Neurological Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35665719" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Neurocysticercosis: an update on diagnosis, treatment, and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30712759" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Neurocysticerosis: An Individualized Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35078088" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : An update on Neurocysticercosis-related epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16804259" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Safety and efficacy of clobazam versus phenytoin-sodium in the antiepileptic drug treatment of solitary cysticercus granulomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33006755" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Carbamazepine versus levetiracetam in epilepsy due to neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35459951" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparative Efficacy and Safety of Lacosamide and Oxcarbazepine for Seizure Control in Children with Newly Diagnosed Solitary Neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26849048" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Albendazole and Corticosteroids for the Treatment of Solitary Cysticercus Granuloma: A Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20739782" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Solitary cysticercus granuloma-treatment with albendazole: what is the optimal duration?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36511204" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Albendazole for Neurocysticercosis in Children: How Long is Long Enough?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14724304" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18495737" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23269591" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21332573" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19325515" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24999157" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26984901" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cysticidal Efficacy of Combined Treatment With Praziquantel and Albendazole for Parenchymal Brain Cysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35213246" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Efficacy of Combination Therapy of Albendazole and Praziquantel vs Albendazole Monotherapy in Children With Persistent Neurocysticercosis: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6881772" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cerebral cysticercosis treated biphasically with dexamethasone and praziquantel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33788843" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The effectiveness of anti-inflammatory and anti-seizure medication for individuals with single enhancing lesion neurocysticercosis: A meta-analysis and expert group-based consensus recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25092547" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Enhanced steroid dosing reduces seizures during antiparasitic treatment for cysticercosis and early after.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32556276" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Frequency and Determinant Factors for Calcification in Neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34793447" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The many facets of disseminated parenchymal brain cysticercosis: A differential diagnosis with important therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32171260" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Quantitative assessment of lesion load and efficacy of 3 cycles of albendazole in disseminated cysticercosis: a prospective evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35864635" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Disseminated Cysticercosis in Indian Scenario - Experience from a Teaching University Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18986841" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28462844" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Understanding the association of neurocysticercosis and mesial temporal lobe epilepsy and its impact on the surgical treatment of patients with drug-resistant epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19270284" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Contemporary neurosurgical approaches to neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32942134" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Endoscopic intervention for intraventricular neurocysticercal cyst: Challenges and outcome analysis from a single institute experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29692305" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intraventricular Neurocysticercosis: Experience and Long-Term Outcome from a Tertiary Referral Center in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16703879" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Bruns syndrome caused by intraventricular neurocysticercosis treated using flexible endoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35854912" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Stereotactic surgery for neurocysticercosis of the 4th ventricle: illustrative cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37879434" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Is Antihelminthics Necessary in Postoperative Treatment of Intraventricular Neurocysticercosis? A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904026" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Characteristics of ventricular shunt malfunctions among patients with neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31642423" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Natural History of Treated Subarachnoid Neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28599004" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Extraparenchymal neurocysticercosis: Demographic, clinicoradiological, and inflammatory features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34232912" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mortality in Parenchymal and Subarachnoid Neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11565520" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19557421" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Intraventricular and subarachnoid basal cisterns neurocysticercosis: a comparative study between traditional treatment versus neuroendoscopic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37810297" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Microsurgical and endoscopic-assisted supraorbital keyhole approach for intra-suprasellar cysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37414569" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Surgical Debulking Before Medical Management in a Patient With Massive Racemose Neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31674300" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Optimal Treatment for Subarachnoid Neurocysticercosis: Closer, but Not There yet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16382035" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30476351" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Factors Associated With Cysticidal Treatment Response in Extraparenchymal Neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31232448" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A Novel, Highly Sensitive Quantitative Polymerase Chain Reaction Assay for the Diagnosis of Subarachnoid and Ventricular Neurocysticercosis and for Assessing Responses to Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17243058" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31454762" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Steroid-sparing agents for the treatment of inflammation in complicated neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32224269" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Systematic Review and Meta-Analysis of Management Strategies and Outcomes in Adult Spinal Neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31279105" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The Role of Flexible Neuroendoscopy in Spinal Neurocysticercosis: Technical Note and Report of 3 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12750103" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Intraocular cysticercosis: clinical characteristics and visual outcome after vitreoretinal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34339720" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cysticercosis in ophthalmology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34723391" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Antiepileptic drugs for seizure control in people with neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31608991" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Antiepileptic drugs for seizure control in people with neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15210888" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Seizure outcome in patients with a solitary cerebral cysticercus granuloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31355931" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7936301" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12629280" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : High prevalence of calcified silent neurocysticercosis in a rural village of Mexico.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
